STOCK TITAN

Surrozen: AI Biotechnology reports 9.9% passive stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

For Surrozen, Inc. (SRZN), AI Biotechnology LLC reported beneficial ownership of 2,212,556 shares, or 9.9% of the common stock. The reported amount includes 1,021,043 shares held directly, including 252,605 acquired in the November 2026 offering, and 1,191,513 shares issuable under warrants treated as beneficially owned. Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik reported the same shared voting and dispositive power figures, while disclaiming beneficial ownership.

AI Biotechnology holds pre-funded warrants for 754,500 shares exercisable at $0.0001 per share and Series E warrants for 757,500 shares exercisable at $11.54 per share. The blocker excludes 320,487 warrant shares from the reported amount. Warrants may not be exercised if doing so would raise beneficial ownership above 9.99%; the limit may be changed by notice effective on the 61st day, subject to a 19.99% maximum.

Beneficial ownership 2,212,556 shares Reported by AI Biotechnology LLC and the related reporting persons
Reported ownership percentage 9.9% Based on the denominator described in the ownership report
Shares held directly 1,021,043 shares Held directly by AI Biotechnology LLC
Pre-funded warrant shares 754,500 shares Exercisable at $0.0001 per share
Series E warrant shares 757,500 shares Exercisable at $11.54 per share
Warrant shares treated as beneficially owned 1,191,513 shares After applying the Beneficial Ownership Blocker
Warrant shares excluded 320,487 shares Excluded due to the Beneficial Ownership Blocker
Beneficial-ownership limit 9.99% Warrants may not be exercised if the limit would be exceeded
Beneficial Ownership Blocker regulatory
"the Beneficial Ownership Blocker"
A beneficial ownership blocker is a legal or structural device that prevents a shareholder from being treated as the ultimate owner of enough shares to trigger control, reporting, or voting thresholds. Think of it like a speed bump that stops an investor from reaching a stake size that would force corporate disclosure or change control rights. Investors care because it affects who controls the company, how shares vote, regulatory filings, takeover risk and therefore potential value or liquidity of their holdings.
Pre-funded Warrants technical
"Pre-funded Warrants exercisable at any time"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Series E Warrants technical
"Series E Warrants exercisable at any time"
Rule 13d-3 regulatory
"as calculated under Rule 13d-3"
Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Surrozen (SRZN) shares does AI Biotechnology report owning?

AI Biotechnology reports beneficial ownership of 2,212,556 shares, or 9.9% of Surrozen's common stock. The amount includes 1,021,043 shares held directly and 1,191,513 shares issuable under warrants treated as beneficially owned.

What is the warrant exercise limit for Surrozen (SRZN) shares?

The warrants may not be exercised above a 9.99% ownership limit if the exercise would cause AI Biotechnology and its affiliates to exceed that level. AI Biotechnology may change the limit by notice to Surrozen, effective on the 61st day after delivery, but may not raise it above 19.99%.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





86889P208

(CUSIP Number)
11/16/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Rows 6, 8 and 9: The total number of shares of common stock, par value $0.0001 per share (the "Common Stock"), of Surrozen, Inc. (the "Issuer") reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology LLC ("AI Biotechnology") and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker (as defined in Item 4), but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker. Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in its November 2026 underwritten public offering (the "Offering"), as reported in the Issuer's Current Report on Form 8-K filed with the SEC on November 16, 2026, and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.


SCHEDULE 13G




Comment for Type of Reporting Person: Rows 6, 8 and 9: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker, but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker. Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in the Offering and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.


SCHEDULE 13G




Comment for Type of Reporting Person: Rows 6, 8 and 9: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker, but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker. Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in the Offering and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.


SCHEDULE 13G




Comment for Type of Reporting Person: Rows 6, 8 and 9: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 1,021,043 shares of Common Stock held directly by AI Biotechnology and (ii) 1,191,513 shares of Common Stock that may be acquired by AI Biotechnology within 60 days of this filing upon the exercise of warrants held directly by AI Biotechnology, after giving effect to the Beneficial Ownership Blocker, but does not include 320,487 shares of Common Stock issuable upon exercise of warrants held directly by AI Biotechnology due to the effect of the Beneficial Ownership Blocker. Row 11: The percent of shares of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 6, 8 and 9 above and, as the denominator, the sum of (i) 19,061,662 shares of Common Stock issued and outstanding as of November 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2026, (ii) 1,894,540 shares of Common Stock issued by the Issuer in the Offering and (iii) 1,191,513 shares of Common Stock issuable upon exercise of warrants held by AI Biotechnology and treated as beneficially owned after giving effect to the Beneficial Ownership Blocker.


SCHEDULE 13G



AI Biotechnology LLC
Signature:/s/ Alejandro Moreno
Name/Title:By: Access Industries Management, LLC, its manager; its Executive Vice President/Alejandro Moreno
Date:11/20/2026
Access Industries Holdings LLC
Signature:/s/ Alejandro Moreno
Name/Title:By: Access Industries Management, LLC, its manager; its Executive Vice President/Alejandro Moreno
Date:11/20/2026
Access Industries Management, LLC
Signature:/s/ Alejandro Moreno
Name/Title:Executive Vice President/Alejandro Moreno
Date:11/20/2026
Len Blavatnik
Signature:*/s/Alejandro Moreno
Name/Title:By: Alejandro Moreno/Attorney-in-Fact
Date:11/20/2026

Comments accompanying signature: * The undersigned, by signing his name hereto, executes this Schedule 13G pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

Keep reading